Literature DB >> 20383521

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Yaroslav Winter1, Karsten Schepelmann, Annika E Spottke, Detlef Claus, Christoph Grothe, Rolf Schröder, Dieter Heuss, Stefan Vielhaber, Björn Tackenberg, Veit Mylius, Jens-Peter Reese, Reinhard Kiefer, Bertold Schrank, Wolfgang H Oertel, Richard Dodel.   

Abstract

Neuromuscular disorders are rare diseases with a chronic and debilitating course. Unfortunately, data on the health-related quality of life (HRQoL) in neuromuscular diseases are limited. The objective of this multicentre cross-sectional study was to compare the HRQoL in patients with amyotrophic lateral sclerosis (ALS), facioscapulohumeral muscular dystrophy (FSHD) and myasthenia gravis (MG) and to identify the determinants of the HRQoL in these diseases. We recruited 91 consecutive outpatients with ALS (n = 37), FSHD (n = 17) or MG (n = 37) in seven specialized German health centres. The HRQoL was determined using the 36-Item Short Form Health Survey (SF-36) and the EuroQol (EQ-5D). Independent predictors of the HRQoL were identified using multiple regression analysis. The HRQoL in all domains of the SF-36, except for bodily pain, was significantly reduced. The domains related to physical health (physical functioning, physical role) were most affected. The EQ-5D-index score was most reduced in ALS (0.54) and least reduced in MG (0.89). Independent predictors of a reduced HRQoL were disease severity and depression in ALS, and disease severity, depression, older age and increased body-mass index in MG. The patterns of HRQoL-impairment in neuromuscular disorders share some common features, such as a more pronounced reduction in the HRQoL related to physical health, but there are a number of disease-specific features that should be considered in outcomes of clinical trials and treatment guidelines. In addition to the treatment of motor symptoms, greater attention should be paid to the treatment of depression, which was found to be among the independent predictors of the HRQoL in ALS and MG.

Entities:  

Mesh:

Year:  2010        PMID: 20383521     DOI: 10.1007/s00415-010-5549-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  44 in total

1.  [The SF-36 in the Federal Health Survey--description of a current normal sample].

Authors:  U Ellert; B M Bellach
Journal:  Gesundheitswesen       Date:  1999-12

2.  A cross sectional study on determinants of quality of life in ALS.

Authors:  A Chiò; A Gauthier; A Montuschi; A Calvo; N Di Vito; P Ghiglione; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

3.  Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study.

Authors:  M Reuther; E A Spottke; J Klotsche; O Riedel; H Peter; K Berger; O Athen; R Köhne-Volland; R C Dodel
Journal:  Parkinsonism Relat Disord       Date:  2006-10-19       Impact factor: 4.891

4.  [Health Status of the German population: results of a representative survey using the EuroQol questionnaire].

Authors:  H H König; S Bernert; M C Angermeyer
Journal:  Gesundheitswesen       Date:  2005-03

5.  What contributes to quality of life in patients with Parkinson's disease?

Authors:  A Schrag; M Jahanshahi; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

6.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Karsten Schepelmann; Yaroslav Winter; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Veit Mylius; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

7.  Health-related quality of life in Huntington's disease: Which factors matter most?

Authors:  Aileen K Ho; Abigail S Gilbert; Sarah L Mason; Anna O Goodman; Roger A Barker
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

8.  Amyotrophic lateral sclerosis severity scale.

Authors:  A D Hillel; R M Miller; K Yorkston; E McDonald; F H Norris; N Konikow
Journal:  Neuroepidemiology       Date:  1989       Impact factor: 3.282

9.  Cross-sectional and longitudinal correlations between disease progression and different health-related quality of life domains in persons with amyotrophic lateral sclerosis.

Authors:  Imelda J M De Groot; Marcel W M Post; Tineke van Heuveln; Leonard H Van den Berg; Eline Lindeman
Journal:  Amyotroph Lateral Scler       Date:  2007-12

10.  Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy.

Authors:  E L van der Kooi; J S Kalkman; E Lindeman; J C M Hendriks; B G M van Engelen; G Bleijenberg; G W Padberg
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

View more
  25 in total

1.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

2.  Quality of life and life circumstances in German myasthenia gravis patients.

Authors:  Sabine Twork; Susanne Wiesmeth; Jörg Klewer; Dieter Pöhlau; Joachim Kugler
Journal:  Health Qual Life Outcomes       Date:  2010-11-11       Impact factor: 3.186

3.  Understanding Symptoms in RYR1-Related Myopathies: A Mixed-Methods Analysis Based on Participants' Experience.

Authors:  Carlos Capella-Peris; Mary M Cosgrove; Irene C Chrismer; M Sonia Razaqyar; Jeffrey S Elliott; Anna Kuo; Magalie Emile-Backer; Katherine G Meilleur
Journal:  Patient       Date:  2020-08       Impact factor: 3.883

4.  Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Ivo Bozovic; Aleksandra Kacar; Stojan Peric; Ana Nikolic; Bogdan Bjelica; Mina Cobeljic; Milutin Petrovic; Aleksandar Stojanov; Vanja Djuric; Miroslav Stojanovic; Gordana Djordjevic; Vesna Martic; Aleksandra Dominovic; Zoran Vukojevic; Ivana Basta
Journal:  J Neurol       Date:  2017-10-30       Impact factor: 4.849

5.  Social/economic costs and health-related quality of life in patients with rare diseases in Europe.

Authors:  Julio López-Bastida; Juan Oliva-Moreno; Renata Linertová; Pedro Serrano-Aguilar
Journal:  Eur J Health Econ       Date:  2016-03-29

6.  Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia).

Authors:  Ivana Z Basta; Tatjana D Pekmezović; Stojan Z Perić; Darija B Kisić-Tepavčević; Vidosava M Rakočević-Stojanović; Zorica D Stević; Dragana V Lavrnić
Journal:  Neurol Sci       Date:  2012-08-09       Impact factor: 3.307

Review 7.  Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.

Authors:  Johannes Brettschneider; Jerome Kurent; Albert Ludolph
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

8.  Patient-identified disease burden in facioscapulohumeral muscular dystrophy.

Authors:  Nicholas E Johnson; Christine Quinn; Eileen Eastwood; Rabi Tawil; Chad R Heatwole
Journal:  Muscle Nerve       Date:  2012-12       Impact factor: 3.217

9.  Family caregiver perspectives on caring for ventilator-assisted individuals at home.

Authors:  Rachel Evans; Michael A Catapano; Dina Brooks; Roger S Goldstein; Monica Avendano
Journal:  Can Respir J       Date:  2012 Nov-Dec       Impact factor: 2.409

10.  Mixed methods analysis of Health-Related Quality of Life in ambulant individuals affected with RYR1-related myopathies pre-post-N-acetylcysteine therapy.

Authors:  Carlos Capella-Peris; Mary M Cosgrove; Irene C Chrismer; Magalie Emile-Backer; M Sonia Razaqyar; Jeffrey S Elliott; Anna Kuo; Paul G Wakim; Katherine G Meilleur
Journal:  Qual Life Res       Date:  2020-02-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.